And then, Ruella et al. [34] introduced that ibrutinib improved the response to the treatment of CD19 CAR-T in mantle cell lymphoma (MCL) and enhanced the xenograft MCL mice lifespan compared with CAR-T cell therapy alone. This evidence concerns the gene CD19 and mantle cell lymphoma.